MedPath

InMed Pharmaceuticals

Ownership
-
Employees
15
Market Cap
-
Website
Introduction

InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It operates through the InMed Pharma and BayMedica segments. The InMed Pharma segment is organized around the research and development of small molecule pharmaceuticals drug candidates. The BayMedica segment focuses on the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Phase 2
Completed
Conditions
Epidermolysis Bullosa Simplex
Epidermolysis Bullosa Dystrophica
Kindler Syndrome
Epidermolysis Bullosa, Junctional
Interventions
Drug: Vehicle Cream
Drug: INM-755 (cannabinol) cream
First Posted Date
2021-06-01
Last Posted Date
2023-07-03
Lead Sponsor
InMed Pharmaceuticals Inc.
Target Recruit Count
19
Registration Number
NCT04908215
Locations
🇫🇷

Hopital Saint Louis APHP Paris, Paris, France

🇫🇷

CHU Toulouse - Hopital Larrey, Toulouse, France

🇬🇷

Andreas Syggros Hospital of Cutaneous Venereal Diseases, Athens, Greece

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath